Literature DB >> 7660886

The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.

A L Jackman1, R Kimbell, M Brown, L Brunton, K R Harrap, J M Wardleworth, F T Boyle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7660886     DOI： 10.1007/978-1-4615-2584-4_40

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  5 in total

Review 1.  Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy.

Authors:  J J McGuire; T Tsukamoto; B P Hart; J K Coward; T I Kalman; J Galivan
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Authors:  Garry H Schwartz; Christopher B Jones; Mitchell Garrison; Amita Patnaik; Chris Takimoto; Heather McCreery; Michael Skinner; Anthony W Tolcher; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

3.  Microwave assisted synthesis of N-arylheterocyclic substituted-4-aminoquinazoline derivatives.

Authors:  Gang Liu; Song Yang; Baoan Song; Wei Xue; Deyu Hu; Linhong Jin; Ping Lu
Journal:  Molecules       Date:  2006-04-10       Impact factor: 4.411

4.  A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus.

Authors:  L A Skelton; M G Ormerod; J Titley; R Kimbell; L A Brunton; A L Jackman
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 5.  New antimetabolites in cancer chemotherapy and their clinical impact.

Authors:  S B Kaye
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.